Growing the Personalized Medicine Market

At Cross Border Biotech, Jeremy Grushcow discusses the stumbling blocks to realizing the 11 percent annual growth rate predicted by PricewaterhouseCoopers for personalized medicine. First, he says, healthcare providers need to learn new approaches and a new language, but, he adds, that “doesn’t mean that the market will grow.” Plus, there are gaps in GINA that could give people pause. “GINA does not expressly cover long-term care and other types of insurance and is focused to some extent on prohibitions on requiring genetic tests,” Grushcow says. The PricewaterhouseCoopers report itself says that pharmaceutical companies would have to rethink their blockbuster drug model and instead consider “a more collaborative model focused on outcomes and specialized therapies.”